{"title": "PDF", "author": "PDF", "url": "www.nitag-resource.org/sites/default/files/37b29f9e2ba54d30f6083260a2a3d1bdb1c67bd2_2.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "JCVI reviewed medical, epidemiologica l, and economic evidence as well as vaccine safety and efficacy data relevant to a herpes zoster (shingles) vaccination programme. Based on t he evidence, the committee recommended that a universal herpes zoster vaccination programme for adults aged 70 up to and including 79 years should be introduced provided that a licensed vaccine is available at a cost effective price. The age range was influenced by data on the burden of disease and the cost-effectivene ss of, and the duration of protection conferred by, vaccination. JCVI will issue a full statement in due course. As with all JCVI recommendations, this recomm endation will be kept under review. "}